Related references
Note: Only part of the references are listed.Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists
Isidoro Gonzalez-Alvaro et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation
Uffe Moller Dohn et al.
CLINICAL RHEUMATOLOGY (2007)
Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein
H. P. Sennels et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2007)
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis
M. Vis et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study
P. L. C. M. van Riel et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production
Y. Morita et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2006)
Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis
AI Catrina et al.
ARTHRITIS AND RHEUMATISM (2006)
Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community
MS Genta et al.
JOINT BONE SPINE (2006)
Rheumatic diseases: the effects of inflammation on bone
NC Walsh et al.
IMMUNOLOGICAL REVIEWS (2005)
Osteopontin as a positive regulator in the osteoclastogenesis of arthritis
T Ishii et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Twenty eight joint count disease activity score in recent onset rheumatoid arthritis using C reactive protein instead of erythrocyte sedimentation rate
T Skogh et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
RF van Vollenhoven et al.
ARTHRITIS RESEARCH & THERAPY (2003)
Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies normal controls
DR Haynes et al.
RHEUMATOLOGY (2003)
The Role of osteopontin in lung disease
A O'Regan
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment
M Ziolkowska et al.
ARTHRITIS AND RHEUMATISM (2002)
Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes
MC Genovese et al.
ARTHRITIS AND RHEUMATISM (2002)
Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice
K Yumoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival
DT Denhardt et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity
S Ashkar et al.
SCIENCE (2000)
Share Paper
